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Onchocerciasis is a parasitic, vector borne disease caused by the ﬁlarial nematode Onchocerca volvulus.
More than 99% of the population at risk of infection live in Africa. Onchocerciasis control was initiated in
West Africa in 1974 with vector control, later complemented by ivermectin mass drug administration and
in the other African endemic countries in 1995 with annual community directed treatment with iver-
mectin (CDTI.) This has signiﬁcantly reduced infection prevalence. Together with proof-of-concept for
onchocerciasis elimination with annual CDTI from foci in Senegal and Mali, this has resulted in targeting
onchocerciasis elimination in selected African countries by 2020 and in 80% of African countries by 2025.
The challenges for meeting these targets include the number of endemic countries where conﬂict has
delayed or interrupted control programmes, cross-border foci, potential emergence of parasite strains
with low susceptibility to ivermectin and co-endemicity of loiasis, another parasitic vector borne disease,
which slows down or prohibits CDTI implementation. Some of these challenges could be addressed with
new drugs or drug combinations with a higher effect on Onchocerca volvulus than ivermectin. This paper
reviews the path from discovery of new compounds to their qualiﬁcation for large scale use and the
support regulatory authorities provide for development of drugs for neglected tropical diseases. The
status of research for new drugs or treatment regimens for onchocerciasis along the path to regulatory
approval and qualiﬁcation for large scale use is reviewed. This research includes new regimens and
combinations of ivermectin and albendazole, antibiotics targeting the O. volvulus endosymbiont Wol-
bachia, ﬂubendazole, moxidectin and emodepside and discovery of new compounds.
© 2016 World Health Organization; licensee Australian Society for Parasitology. This is an open access
article under the CC BY IGO 3.0 license (https://creativecommons.org/licenses/by/3.0/igo/).Contents
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1.1. OnchocerciasisDr. Awadzi (13.06.1939-16.03.2011)
Father of ethical, systematic and evidence based clinical research in
onchocerciasis Dr. Awadzi was instrumental in development of the
methods for assessing the efﬁcacy and safety of anti-onchocercal
drugs, providing training and collaboration for many young scien-
tists and physicians. He evaluated nearly all drug candidates for
onchocerciasis proposed before and after the development of
ivermectin. This picture shows him with the case report forms of
the last clinical trial he lead as principal investigator, the Phase 2
study of moxidectin. He then ‘retired’ and was the scientiﬁc advisor
on the Phase 3 study and trained, together with his collaborators at
the Onchocerciasis Chemotherapy Research Center, Hohoe, Ghana
(now University of Health and Allied Sciences Research Centre
(UHASRC), School of Public Health, Ghana) the principal in-
vestigators of that study in Liberia and the Democratic Republic of
the Congo.Onchocerciasis (river blindness) is a parasitic, vector borne
disease caused by the ﬁlarial nematode Onchocerca volvulus. Four
life stages of Onchocerca volvulus live in humans: the infective (L3)
larvae injected by the vector undergo two moultings to develop via
L4 larvae into juvenile adults (L5) and mature to reproductively
competent adults (macroﬁlariae) within around 1 year (Duke,1991;
Basanez and Ricardez-Esquinca, 2001). The macroﬁlariae (adult
worms) have an estimated mean reproductive life span of 9e11
years (Plaisier et al., 1991), reside primarily in subcutaneous and
deep tissue nodules and produce embryos (microﬁlariae). The
microﬁlariae live for around 1 year, reside primarily in the sub-
epidermal layer of the dermis and can invade the eyes. Theimmunological response to the death of the microﬁlariae, which
includes inﬂammatory components, is responsible for the symp-
toms of the disease which range from itching to blindness. The
vectors are species of the genus Simulium (black ﬂies), in Africa
primarily Simulium damnosum s.l.. During a blood meal, the
blackﬂies ingest microﬁlariae present in the skin which develop
into infective (L3) larvae. Transmission of the infective larvae to
humans upon another blood meal closes the transmission cycle
(World Health Organization, 1995).
1.2. Onchocerciasis control programmes
The signiﬁcant public health and resulting socio-economic
burden of onchocerciasis have motivated large scale disease con-
trol and elimination programmes in all endemic countries. The vast
majority of these countries are in Africa, where more than 100
Million people live in onchocerciasis endemic areas (Noma et al.,
2014; Zoure et al., 2014; O’Hanlon et al., 2016). Around 0.56
Million people were estimated to live in the 13 small endemic foci
in 6 countries in Central and South America (Center for Disease
Control (CDC), 2013) and around 0.3 Million in Yemen
(Mackenzie et al., 2012) Onchocerciasis control started in 1974 with
the Onchocerciasis Control Programme in West Africa (OCP) which
conducted large scale larviciding of vector breeding sites in the
West African Savannah. The vector-control based strategy was
complemented with mass drug administration (MDA) (Boatin and
Richards, Jr. 2006) after ivermectin (Mectizan®) had been regis-
tered and Merck decided to donate ivermectin for onchocerciasis
control for as long and in the amounts needed (Campbell, 2012). At
the closure of OCP in 2002, onchocerciasis had been eliminated as a
public health problem in the programme area (Benton et al., 1998;
Boatin, 2008; Campbell, 2012).
Mass ivermectin administration was the sole strategy in the
countries of the Onchocerciasis Elimination Program for the
Americas (OEPA). The public health system distributed ivermectin
initially annually, then twice yearly in all villages in which oncho-
cerciasis was endemic. This was complemented for several years by
two additional distributions in the majority of hyper-endemic
communities (60% prevalence before the start of interventions)
and a few meso-endemic communities (20% to <60% prevalence
before start of interventions). In all but the large focus spanning
areas of Venezuela and Brazil, this strategy has or is likely to have
permanently interrupted transmission of the parasite (Convit et al.,
2013; Anonymous 2013; West et al., 2013; Center for Disease
Control (CDC), 2013; Lovato et al., 2014; Rodriguez-Perez et al.,
2015; Anonymous 2015).
In Yemen, ivermectin has been offered since 1992 at least
biannually to those with symptoms (Al-Qubati, 1994; Al-Qubati
et al., 1997). Yemen is targeting onchocerciasis elimination
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vector control (World Health Organization, 2012a).
In 1995, the African Programme for Onchocerciasis Control
(APOC) was launched in view of eliminating onchocerciasis as a
public health problem in the African countries not covered by the
OCP (Roungou et al., 2015; Fobi et al., 2015). The strategy was
annual community-directed treatment with ivermectin (CDTI) in
all communities where onchocerciasis was meso- or hyper-
endemic (Noma et al., 2014). In 2014, around 112 Million people
received ivermectin in the 22 countries which reported data to
APOC. Treatment data from another 4 countries implementing CDTI
had not been reported to APOC (African Programme for Oncho-
cerciasis Control (APOC) 2015b). Field-based as well as modelling
studies of the impact of annual CDTI show that in areas with long
term CDTI, onchocerciasis has indeed been eliminated as a public
health problem (Ozoh et al., 2011; Coffeng et al., 2013, 2014b;
Turner et al., 2014).
1.3. Ivermectin - the ’standard of control’
Ivermectin exerts a ’microﬁlaricidal’ effect which results in near
elimination of microﬁlariae from the skin within a few days and a
so called ’embryostatic’ effect which temporarily prevents release
of microﬁlariae by the macroﬁlariae (Basanez et al., 2008).
Together, these effects result in long term reduction of microﬁlariae
levels in infected people. The speed and extent of reduction of skin
microﬁlariae levels as well as the time and extent of repopulation of
the skin with microﬁlariae vary between people (Churcher et al.,
2009; Awadzi et al., 2014). Time and rate of repopulation of the
skin have been linked to host factors, including the immune
competence (Ali et al., 2002) and the number of palpable nodules, a
’proxy’ for the number of macroﬁlariae (Pion et al., 2011). Reduction
of microﬁlariae levels prevents appearance of new symptoms,
eliminates reversible symptoms of the disease, prevents progres-
sion of irreversible symptoms and reduces parasite transmission.
Ivermectin is suitable for MDA because it has an excellent safety
proﬁle: adverse reactions are due to the efﬁcacy of the drug, i.e. the
immunological reaction of the body to the death of the micro-
ﬁlariae which includes inﬂammatory components (Mackenzie
et al., 2003). These are referred to as ’Mazzotti reactions’ and are
in most cases mild to moderate and disappear within a few days
without treatment (Awadzi, 1980; DeSole et al., 1989a, 1989b;
Awadzi et al., 1990) even at doses higher than the one used in
onchocerciasis control programmes (150 mg/kg) (Awadzi et al.,
1999).
Severe adverse reactions to ivermectin treatment different from
Mazzotti reactions can, however, occur in people heavily infected
with the ﬁlarial parasite Loa loa. These reactions can have sequelae,
be live-threatening and have even led to death. The risk of severe
adverse reactions increases with the intensity of infection as
measured by the microﬁlarial load. People in whom this load ex-
ceeds 30,000 microﬁlariae/ml blood are at particular risk of re-
actions that result in at least several days of incapacity to conduct
normal everyday activities without assistance (Gardon et al., 1997;
Boussinesq et al., 1998, 2003; Scientiﬁc Working Group on Serious
Adverse Events in Loa Loa endemic areas, 2003; Twum-Danso and
Meredith, 2003; Twum-Danso, 2003a, 2003b). Loa loa is endemic in
the equatorial forest areas of Central and West Africa. Its distribu-
tion has been mapped using a rapid assessment method (Zoure
et al., 2011). In Loa loa endemic areas where onchocerciasis is
meso- or hyperendemic, the beneﬁt of ivermectin treatment is
considered to exceed the risk of severe adverse reactions provided
CDTI is implemented with special precautions to ensure that
appropriate care is available for people developing severe adverse
reactions. In contrast, in Loa loa endemic areas whereonchocerciasis is hypoendemic, CDTI cannot be implemented at all
and treatment with ivermectin needs to be individual, clinic-based
(Mectizan Expert Committee and APOC Technical Consultative
Committee, 2004).
The severe adverse reactions to ivermectin in people highly
infected with Loa loa also delay progress towards elimination of
lymphatic ﬁlariasis (LF) in Africa where the ’standard of control’ is
co-administration of ivermectin and albendazole. People with LF do
not directly beneﬁt from ivermectin treatment since the symptoms
of LF are due to themacroﬁlariae. Consequently, use of ivermectin in
areas co-endemic for LFand Loa loa, butnot at leastmesoendemic for
onchocerciasis, does not have an acceptable risk-beneﬁt ratio. The
provisional strategy for LF control in Loa loa co-endemic areas is
twice yearly treatment with 400 mg albendazole complemented
with vector control (World Health Organization, 2012b). This strat-
egy is now supported by the results of a community trial of semi-
annual MDA with 400 mg albendazole. The study showed that the
geometric mean microﬁlariae level 12 months after the ﬁrst treat-
ment was reduced by 60% relative to the pre-treatment level (Pion
et al., 2015). Co-infections with other ﬁlariae do not appear to
signiﬁcantly affect the adverse reaction proﬁle of ivermectin, pre-
sumably because parasite numbers are lowrelative to those inheavy
Loa loa infections.
1.4. Moving towards onchocerciasis elimination in Africa
APOC was formed to support onchocerciasis endemic countries
in establishing sustainable CDTI for control of onchocerciasis as a
public health problem. At the time, it was considered impossible to
eliminate onchocerciasis in Africa with CDTI alone (Dadzie et al.,
2003).
Since then, a study in two onchocerciasis hyperendemic foci in
Mali and Senegal has provided proof-of-concept that long term
annual CDTI can eliminate onchocerciasis infection and perma-
nently interrupt parasite transmission in Africa (Diawara et al.,
2009; Traore et al., 2012). Encouraged by these results, APOC con-
ducted large scale evaluation of the prevalence of infection and
intensity of microﬁlaridermia in areas under long term CDTI. In
close to 90% of the areas evaluated, prevalence of infection had
decreased to or even below the level predicted by the onchocer-
ciasis transmission model ONCHOSIM (Plaisier et al., 1990; Remme
et al., 1990) when the pre-CDTI endemicity, the percentage of the
population which participated in CDTI and the number of years of
CDTI were taken into account (Plaisier et al., 1990; African
Programme for Onchocerciasis Control (APOC) 2009; African
Programme for Onchocerciasis Control (APOC) 2010a; African
Programme for Onchocerciasis Control (APOC) 2011; Tekle et al.,
2012; African Programme for Onchocerciasis Control (APOC)
2012a; African Programme for Onchocerciasis Control (APOC)
2013; African Programme for Onchocerciasis Control (APOC)
2014; Stolk et al., 2015; African Programme for Onchocerciasis
Control (APOC) 2015a; African Programme for Onchocerciasis
Control (APOC) 2015b). In the isolated meso-endemic focus Abu
Hamed in the North of Sudan, annual CDTI initiated in 1998 and
biannual CDTI from 2006 onward has interrupted transmission of
the parasite (Higazi et al., 2013; Zarroug et al., 2014).
The proof-of-concept in Mali and Senegal and the decrease in
infection prevalence in APOC countries resulted in expansion of the
objectives of APOC and the onchocerciasis endemic countries in
Africa to include elimination of onchocerciasis in 80% of African
countries by 2025 (African Programme for Onchocerciasis Control
(APOC) 2012b). Elimination of onchocerciasis in selected African
countries was included among the WHO 2015e2020 targets for
elimination or eradication of neglected tropical diseases (World
Health Organization, 2012a).
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elimination with ivermectin treatment in Africa
Fig. 1 shows the framework for elimination of onchocerciasis
developed by APOC (African Programme for Onchocerciasis Control
(APOC) 2010b).
In Phase 1, the intervention phase, implementation of annual
CDTI leads to a progressive reduction of prevalence and intensity of
infection in the population, usually quantitated via the ’Community
Microﬁlariae Load’ (CMFL, the geometric mean of the number of
microﬁlaria/snip of skin in a sample of >20 year old adults) (Remme
et al., 1986). These reductions are the consequence of the killing of
the vast majority of the skin microﬁlariae present in the human
population within days of ivermectin treatment due to the ’micro-
ﬁlaricidal’ effect of ivermectin and the subsequent slow increase in
skin microﬁlariae levels until the next treatment round (Fig. 2). The
reduction in CMFL reduces the level of parasite transmission.
Consequently, the macroﬁlariae population in the human popula-
tion gradually decreases since the rate with which macroﬁlariae
reach the end of their reproductive life span exceeds the rate of new
infections reaching the adult life stage. When parasitological and
entomological evaluations show that parasite levels in the humanand vector populations have reached a level too low to sustain
transmission across the whole transmission zone, CDTI can be dis-
continued. Phase 2 begins during which evaluations to verify that
elimination has indeed been achieved are conducted. If elimination
is conﬁrmed, surveillance for timely detection of re-introduction of
infection (or re-emergence in caseof ’falsenegative’ conclusion from
the veriﬁcation of elimination) is initiated (Fig. 1).
New WHO guidelines for determining when treatment can be
stopped and for verifying that transmission has been interrupted
have become available. They include ’strong recommendations’ for
testing the heads of black ﬂies for O. volvulus DNA, i.e. for infective
larvae (based on ’high certainty of evidence’) and testing of children
under 10 years for presence of antibodies against the O. volvulus
antigen Ov-16 (based on ’low certainty of evidence’). Only children
are tested because the test detects patent as well as past infection.
Consequently, other tests are needed to conﬁrm patent infection in
case of detection of antibodies to Ov-16 (World Health
Organization, 2016).
The duration of the intervention phase depends on the CMFL
before introduction of CDTI and the effectiveness of CDTI (Fig. 3).
The pre-CDTI CMFL is a function of vector abundance and vector
species since species differ with respect to their competency as
Fig. 3. Trends in prevalence of people with detectable levels of skin microﬁlariae and community microﬁlarial load. CMFL - community microﬁlarial load. Mf - microﬁlariae. From:
(African Programme for Onchocerciasis Control (APOC) 2010b). Prevalence refers to prevalence of people with levels of skin microﬁlariae detectable when two snips of skin are
obtained and examined microscopically for presence of microﬁlariae, not to prevalence of infection.
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a number of factors including:
1. The vector species and abundance.
2. The percentage of the ’transmission zone’ in which CDTI is
provided. A transmission zone is ’a geographical area where
transmission of O. volvulus occurs by locally breeding vectors
and which can be regarded as a natural ecological and epide-
miological unit for interventions’ (African Programme for
Onchocerciasis Control (APOC) 2010b).
3. The percentage of the eligible population which participates in
CDTI (referred to as ’treatment coverage’) and the percentage of
the population which never (or very rarely) takes ivermectin
(referred to as ’systematic non-compliers’) (Turner et al., 2013;
Coffeng et al., 2014a). The percentage of systematic non-
compliers can be extensive. A study conducted among 8480
villagers from 101 villages in Cameroon and Nigeria after 8 years
of CDTI showed that 5.9%, 8.5% and 12.3%, respectively had
never, only once or only twice taken ivermectin (Brieger et al.,
2011).
4. The susceptibility of O. volvulus to ivermectin and/or the level of
immune competency of the host (see Section 1.6).1.6. Challenges for elimination of onchocerciasis in Africa
The area over which onchocerciasis is endemic in Africa is huge.
The latest updateof the areas requiring interventions for elimination
of onchocerciasis indicates that 172 Million people require treat-
ment (African Programme forOnchocerciasis Control (APOC) 2015a;
African Programme for Onchocerciasis Control (APOC) 2015b). A
large number of endemic areas extend across country borders
(Noma et al., 2014), including countries with different health care
system capacity and history and risk of conﬂict. Both within and
across countries, the startof CDTI implementation, the timeatwhich
full geographic and high treatment coverage were achieved as well
as the extent of therapeutic coverage differ between geographic
areas whichmay belong to the same transmission zone. Large areas
are loiasis co-endemic (Zoure et al., 2011). Loiasis co-endemicity
prohibits implementation of CDTI in onchocerciasis hypoendemicareas. Themodiﬁed CDTI implementation strategy in onchocerciasis
meso- or hyperendemic areas allows only a slow scale up to 100%
geographic coverage (Mectizan Expert Committee and APOC
Technical Consultative Committee, 2004). Furthermore, severe
adverse reactions to ivermectin in loiasis co-endemic areas under-
standably reduce the willingness of the population to participate in
CDTI (Haselowet al., 2003). In a Loa loa co-endemic areawhere CDTI
had been going on for 10e12 years and severe adverse reactions had
occurred at the start of CDTI, only 18% of participants had taken
ivermectin at least 7 times, while 40.4% had taken ivermectin only
1e3 times and 15.5% had never taken ivermectin (Wanji et al., 2015).
Finally, higher than anticipated prevalence of infection in areas
under long term CDTI in Ghana and Cameroon have raised concern
about emergence of parasites with low susceptibility to the
embryostatic effect of ivermectin (Awadzi et al., 2004a, 2004b; Osei-
Atweneboana et al., 2007, 2011; Churcher et al., 2009; Pion et al.,
2011; Pion et al. 2013; Nana-Djeunga et al., 2014; Lamberton et al.,
2015). The fact that the response to the embryostatic effect can only
be evaluated via repeated snipping of skin and microscopic exami-
nation for the number of microﬁlariae emerged after 24 h of incu-
bation in physiological saline solution (Awadzi et al., 2004b; Osei-
Atweneboana et al., 2007; Pion et al., 2011) makes it difﬁcult to
evaluate whether the frequency of people harboring parasites with
low susceptibility to the embryostatic effect of ivermectin is
increasing. The role of immunocompetency, linked to fast repopu-
lation of the skin with microﬁlariae observed in Sudan (Ali et al.,
2002), has not yet been evaluated. Furthermore, ’suboptimal
response’ to ivermectin has also been observed in CDTI naive areas
(Bakajika et al., 2013).
Many of these challenges can be addressed by improving
implementation of CDTI, ideally supported by the results of social
research to optimize community participation and achieve the
100% geographic and 80% treatment coverage recommended by
APOC for elimination of onchocerciasis with annual CDTI. Bian-
nual CDTI as conducted or planned in some areas in Africa may
address other challenges, such as the emergence of parasites with
low susceptibility to the embryostatic effect of ivermectin and the
need to ’harmonize’ progress towards elimination across the
different geographic areas belonging to the same transmission
zone.
Table 1
Challenges for accelerating progress towards elimination of onchocerciasis in Africa that can be addressed through availability of drugs other than ivermectin.
Challenges ‘Efﬁcacy proﬁle’ of new treatments
 Achieving at least 80% treatment coverage across 100% of the geographic area of each transmission zone
 Accelerating reduction in infection prevalence and transmission in areas of a transmission zone where CDTI
implementation started late, was implemented with low treatment coverage or interrupted due to conﬂict
 O. volvulus strains with low susceptibility to ivermectin
 Treatment regimen(s)/drug(s) with higher efﬁcacy
against O. volvulus than ivermectin
 Co-endemicity of Loiasis  Drugs effective against O. volvulus without a cidal effect
on Loa loa microﬁlariae
 Drugs with a sterilizing or cidal effect on Loa loa
macroﬁlariae
Implementation Research 
studies (5000+)
Regulatory review
Phase 3 (1000+)
Phase 2 (100+)
Phase 1 (20+)
Clinical Development
Pre-clinical development
Discovery
1-2*
2-5*
3-7*
250**
1*
Fig. 4. Stages, terminology and historical success rates during research of new drugs. Discovery: Testing of thousands of compounds in computer models, in vitro and in animal
models with emphasis on evaluating whether the compounds have the desired efﬁcacy. Pre-clinical development: Testing of compounds in vitro and in animal models with
emphasis on evaluating the toxicity. On average around 5 of 250 compounds entering pre-clinical development are progressed to clinical development, i.e. are tested in humans. It
was estimated that it takes 3e6 years to identify a compound that can enter clinical development. Clinical development consists of three phases. Phase 1 studies occur typically in
small groups of healthy volunteers. Out of 3e7 compounds tested in Phase 1 studies, 2e5 compounds enter Phase 2 studies. Phase 2 studies are typically the ﬁrst studies in people
who have the disease intended to be treated. Out of 2e5 compounds tested in Phase 2 studies, 1e2 enter Phase 3 studies. Phase 3 studies are typically conducted in 1000 people.
Of 1e2 compounds tested in Phase 3 studies, one has the properties which result in submission for marketing approval by the US FDA. * Failure rates based on Congress of the
United States, Congressional Budget Ofﬁce, Research and Development in the Pharmaceutical Industry, October 2006 (http://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.
pdf, accessed 16 January 2016) ** Failure rate based on estimate of International Federation of Pharmaceutical Manufacturer’s Association (IFPMA) presented to the WHO Expert
Working Group on Funding R&D for Diseases of the Developing World (http://www.who.int/phi/IFPMA_FundingR&D_Jan09.ppt, access 16 January 2016).
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of African endemic countries by 2025 require new drugs. These need
to have treatment regimens and safety proﬁles suitable for MDA or
large scale individualized treatment within the health care capac-
ities of the endemic countries as well as appropriate efﬁcacy proﬁles
(Table 1). From their conception, onchocerciasis control programmes
have worked closely with researchers to address the challenges the
programmes faced at different stages (Remme, 2004).1.7. The path from discovery to qualiﬁcation of drugs for human use
Fig. 4 illustrates the different stages during research for new
drugs to registration by a regulatory authority (i.e. approval of use
in humans for a speciﬁed indication, formulation and dose regimen,
also referred to as ’marketing authorization’) and qualiﬁcation for
large scale use in resource limited settings.
In contrast to discovery research, pre-clinical (non-clinical)
development and clinical development need to be conducted ac-
cording to guidance provided by regulatory agencies. The ’Inter-
national Conference for Harmonisation on Technical Requirements
for Registration of Pharmaceuticals for Human Use’ (ICH) was
formed to harmonize regulatory requirements between the US,
Europe and Japan. The ICH website includes the large number of
guidance documents issued to date. ICH guidelines are not available
for all testing required. Both the US regulatory agency (Food and
Drug Administration (FDA)) and the European regulatory agency
(European Medicines Agency (EMA)) give advice on drug devel-
opment at request. Their websites include guidance on topics notcovered by ICH guidelines. Table 3 provides websites and deﬁnition
of some drug development terms.1.7.1. Pre-clinical (non-clinical) development
The objective of pre-clinical studies (also referred to as non-
clinical studies) is to characterize the toxicity proﬁle of a com-
pound in terms of dose-response relationship, organs affected and
reversibility of effects. A number of non-clinical studies required for
registration may be conducted in parallel to clinical development.
Guidance on what studies are required before initiation of clinical
development is available. As clinical development proceeds, longer
dosing schedules are evaluated and more participants are enrolled
(see Fig. 4), additional non-clinical studies are required (e.g. ICH
Guideline M3).
Pre-clinical studies include safety pharmacology and pharma-
codynamic studies, toxicokinetic and pharmacokinetic studies,
single and repeated dose studies to determine acute, subchronic
and chronic toxicity, reproductive toxicity studies and genotoxicity
studies. Carcinogenicity studies are required for compounds
intended to have long treatment regimens and may be required for
other compounds. Juvenile toxicity studies need to be conducted
for compounds for paediatric use. Other types of non-clinical
studies are dependent on compound characteristics, indication or
as indicated by the results of other pre-clinical studies. Toxicity
studies are conducted in vitro and in several animal species (rodent
and non-rodent) to identify the species that provides the most
appropriate model for a particular compound. With the exception
of mode of action studies, usually conducted during discovery
Table 2
Website references.
Priority review voucher http://www.priorityreviewvoucher.org/, accessed 8 April 2016
Development of new regimens of ivermectin
and albendazole
DOLF project (Death to Onchocerciasis and Lymphatic Filariasis) website: www.dolf.wustl.edu, accessed 10 January 2016
Discovery and development of antibiotics A-WOL consortium: http://a-wol.com/
University of Bonn (clinical development of anti-Wolbachia antibiotics):
www.microbiology-bonn.de/immip/science
Doxycycline label:
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm, accessed 8 April 2016
Development of ﬂubendazole Bill and Melinda Gates foundation funding: http://www.dndi.org/media-centre/press-releases/918-ﬂubendazole.html,
accessed 8 April 2016.
Johnson&Johnson involvement: http://www.jnj.com/news/all/johnson-and-johnson-joins-public-and-private-partners-
in-the-largest-coordinated-action-to-date-to-eliminate-or-control-neglected-tropical-diseases, accessed 8 April 2016.
DNDi involvement: http://www.dndi.org/diseases-projects/portfolio/completed-projects/ﬂubendazole-macroﬁlaricide/,
accessed 8 April 2016.
Registration of moxidectin Medicines Development for Global Health:
http://www.medicinesdevelopment.com/, accessed 8 April 2016
Global Health Investment Fund: www.ghif.com,
http://www.ghif.com/uncategorized/press-release-moxidectin/, www.who.int/tdr/news/2015/moxi-treatmt-funding/
en/index.html; both accessed 8 April 2016.
Development of emodepside Labeling of emodepside containing products for veterinary use:
http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId¼WC500063849,
accessed 8 April 2016; http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/
veterinary/002006/WC500106176.pdf, accessed 8 April 2016; www.fda.gov/downloads/animalveterinary/products/
approvedanimaldrugproducts/foiadrugsummaries/ucm062332.pdf; accessed 8 April 2016.
DNDi and Bayer Health care agreement on development of emodepside: http://www.dndi.org/diseases-projects/
portfolio/emodepside/, accessed 15 January 2016.
Discovery of macroﬁlaricidal drug candidates University of California, San Francisco; Anacor; Lindsey F. Kimball Research Institute, N.Y. Blood Center; San Francisco
State University http://tintin.sfsu.edu/gatesAward.html, accessed 8 April 2016
Websites with guidance on development of
drugs for veterinary use
US FDA: http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm
EMA:
http://www.ema.europa.eu/ema/index.jsp?curl¼pages/regulation/landing/veterinary_medicines_regulatory.jsp&mid¼
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’Good Laboratory Practice’ to support registration.
1.7.2. Clinical development
Clinical development typically proceeds in 3 phases, but ’mixed
phase’ studies are becoming more frequent.
Phase 1 studies occur typically in small groups of healthy vol-
unteers. They are initiated with single ascending dose studies fol-
lowed by multiple ascending dose studies if the intended dosing
regimen includes multiple doses. Phase 1 studies are designed to
determine the safety and pharmacokinetics of doses that can be
expected to be efﬁcacious based on the data from Discovery and
pre-clinical development and whether the compound causes any
adverse reactions that would prohibit further development. Phase
1 studies are also conducted to evaluate the pharmacokinetics, ef-
ﬁcacy and safety in particular subpopulations (e.g. children, people
with impaired liver or kidney function). Phase 1 studies in sub-
populations may be conducted in parallel to Phase 2 or 3 studies.
Phase 2 studies are the ﬁrst studies in people who have the dis-
ease intended to be treated. They are conducted in medium sized
groups to determine whether the compound is likely to have the
intended therapeutic effectwithoutunacceptable adverse reactions.
Phase 3 studies are typically conducted in 1000 people. They
are designed to test the hypothesis that the compound is as or more
efﬁcacious than the compound used for comparison (usually the
’standard of care’) and does not result in a level of adverse reactions
not acceptable in the target population.
It was estimated that it takes around 6e7 years from the start of
clinical development to submission to regulatory authorities for
marketing approval (Dimasi et al., 2003; Congress of the United
States - Congressional Budget Ofﬁce, 2006; Pharmaceutical
Research and Manufacturers of America, 2007; International
Federation of Pharmaceutical Manufacturers & Associations, 2009;
Food and Drug Administration of the United States of America, 2012).
At the time of registration, the regulatory authorities may
require commitment to conduct additional studies (post-marketingstudies, Phase 4 studies).
1.7.3. Implementation research
For drugs intended for MDA (i.e. large scale use without diag-
nosis and treatment supervision by health care personnel), large
scale trials (community studies) involving thousands of people are
conducted to obtain additional data on the safety, efﬁcacy and/or
effectiveness of the drugs (Remme et al., 1989; DeSole et al., 1989a,
1989b; Horton et al., 2000). Interventions intended for MDA and for
individualized use in resource-limited settings also require imple-
mentation research. The studies are designed to understand and
identify how to overcome barriers to effective use of the inter-
vention. Such research resulted in e.g. the CDTI strategy and
expansion of the strategy for delivery of other health interventions.
Implementation research also provided the basis for todays strat-
egy of home management of malaria (Horstick et al., 2010; Ajayi
et al., 2013; Brieger et al., 2015; Sommerfeld et al., 2015). An
implementation research tool kit is available http://www.who.int/
tdr/publications/topics/ir-toolkit/en/(accessed 16 January 2016).
1.8. Regulatory agency advice and incentives for development of
drugs for neglected tropical diseases
Both EMA and FDA try to encourage development of drugs for
neglected tropical diseases through different mechanisms (Cole,
2010). This includes special provisions for advice on the develop-
ment plan and/or assistance for development of study protocols.
The EMA provides ’scientiﬁc opinions’ for medicines (drugs,
vaccines) to prevent or treat diseases of major public health interest
outside the European Union (EU) in co-operation with WHO ac-
cording to Article 58 of EC regulation 726/2004. Submissions for a
’scientiﬁc opinion’ undergo EMA assessment of quality, safety and
efﬁcacy according to the standards applied to submissions for
registration/marketing authorization in the EU but in collaboration
withWHO and regulatory agencies from non-EU countries (Table 2).
Since 2007, the US is incentivising investments into drug
Table 3
Drug development terms and websites with information on drugs and drug development.
International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) and ICH guidelines
http://www.ich.org/about/history.html.
ICH ‘Quality guidelines’ (qualiﬁcation of drug substance, drug product and drug
manufacturing): http://www.ich.org/products/guidelines/quality/article/quality-
guidelines.html
ICH ‘Safety guidelines’ (pre-clinical development):
http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html
ICH ‘Efﬁcacy guidelines’ (clinical development):
http://www.ich.org/products/guidelines/efﬁcacy/article/efﬁcacy-guidelines.html
ICH ‘Multidisciplinary guidelines’ (e.g. Medical Dictionary for Regulatory Activities,
guidance for nonclinical safety studies required to support the different stages of clinical
development):
http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-
guidelines.html
US FDA US Food and Drug Administration: http://www.fda.gov/
Guidances: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/default.htm
EMA European Medicines Agency: http://www.ema.europa.eu/ema/
Guidelines:
http://www.ema.europa.eu/ema/index.jsp?curl¼pages/regulation/general/general_
content_000043.jsp&mid¼WC0b01ac05800240cb
Paediatric investigation plans: http://www.ema.europa.eu/ema/index.jsp?curl¼pages/
medicines/landing/pip_search.jsp&mid¼WC0b01ac058001d129
Regulatory agency websites US Food and Drug Administration: FDA, http://www.fda.gov/
European regulatory agency (European Medicines Agency, EMA):
http://www.ema.europa.eu/ema/
EMA Scientiﬁc Opinions for medicines for use outside the European Union:
http://www.ema.europa.eu/ema/index.jsp?curl¼pages/regulation/general/general_
content_000312.jsp&mid¼WC0b01ac058001d12c
Public assessment reports, Summary basis of approval Documents summarizing the assessment of the data submitted by the reviewers assigned
by the regulatory authority. They include signiﬁcantly more details than the label,
prescribing information or package insert.
European Public Assessment Reports: http://www.ema.europa.eu/ema/index.jsp?
curl¼pages/medicines/landing/epar_search.jsp&mid¼WC0b01ac058001d124,
Australian Public Assessment Reports: https://www.tga.gov.au/australian-public-
assessment-reports-prescription-medicines-auspars
US FDA for drugs: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
US FDA for biologics: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/
ApprovedProducts/LicensedProductsBLAs/
Product label, prescribing information, package insert Documents summarizing information on the formulation, the results of pre-clinical
development and clinical development, dosing and indications approved by the regulatory
authorities. Agencies other than the ones listed below make labels publicly available on
their websites.
US Food and Drug Administration: http://labels.fda.gov/
European Medicines Agency: http://www.ema.europa.eu/ema/index.jsp?curl¼pages/
medicines/landing/epar_search.jsp&mid¼WC0b01ac058001d124,
Australian Therapeutic Goods Administration: https://www.tga.gov.au/australian-public-
assessment-reports-prescription-medicines-auspars
Investigational drug ’A pharmaceutical form of an active ingredient or placebo being tested or used as a
reference in a clinical trial, including a product with a marketing authorization when used
or assembled (formulated or packaged) in a way different from the approved form, or when
used for an unapproved indication, or when used to gain further information about an
approved use.’, see e.g. ICH E6 Good Clinical Practice, http://www.ich.org/products/
guidelines/efﬁcacy/article/efﬁcacy-guidelines.html, accessed 16 January 2016
Approved formulations and indications for the same active pharmaceutical ingredient
(drug substance) may differ between countries.
Adverse event (AE) Any untoward medical occurrence in a patient or clinical investigation subject
administered a pharmaceutical product and which does not necessarily have to have a
causal relationship with this treatment (ICH E6 Good Clinical Practice: http://www.ich.org/
ﬁleadmin/Public_Web_Site/ICH_Products/Guidelines/Efﬁcacy/E6/E6_R1_Guideline.pdf)
Adverse drug reaction, adverse reaction (ADR) For marketed medicinal products:
A response to a drug which is noxious and unintended and which occurs at doses normally
used in man for prophylaxis, diagnosis, or therapy of disease or for modiﬁcation of
physiological function.
For new medicinal products or new uses of approved products:
All noxious and unintended responses to a medicinal product related to any dose should be
considered adverse drug reactions (ICH E6 Good Clinical Practice)
Serious adverse event (SAE) and serious adverse drug reaction (SAR) A serious adverse event (experience) or reaction is any untoward medical occurrence that
at any dose:
- results in death,
- is life-threatening,
NOTE: The term “life-threatening” in the deﬁnition of “serious” refers to an event in which
the patient was at risk of death at the time of the event; it does not refer to an event which
hypothetically might have caused death if it were more severe.
- requires inpatient hospitalisation or prolongation of existing hospitalisation,
- results in persistent or signiﬁcant disability/incapacity, or
- is a congenital anomaly/birth defect.
(continued on next page)
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Table 3 (continued )
Important medical events that may not be immediately life-threatening or result in death
or hospitalisation but may jeopardise the patient or may require intervention to prevent
one of the other outcomes listed in the deﬁnition above should also usually be considered
serious.
Note: The terms ’serious’ and ’severe’ are not synonymous.
The term “severe” is often used to describe the intensity (severity) of a speciﬁc event (as in
mild, moderate, or severe myocardial infarction); the event itself, however, may be of
relatively minor medical signiﬁcance (such as severe headache). This is not the same as
“serious,” which is based on patient/event outcome or action criteria usually associated
with events that pose a threat to a patient’s life or functioning. Seriousness (not severity)
serves as a guide for deﬁning regulatory reporting obligations.
(ICH E6 Good Clinical Practice)
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view vouchers’ (PRV) for organisations which register a drug for a
qualifying disease. The PRV is based on a proposal developed by
Ridley and colleagues (Ridley et al., 2006) and has also been sug-
gested for Europe (Ridley and Sanchez, 2010). The PRV guarantees
an FDA decision on the submission for another drug within 6
months and can be sold. For drugs with high economic potential, a
reduction of the normal submission review period from 10 or more
months to 6months can result in signiﬁcant proﬁt since it increases
the duration of market exclusivity (i.e. time during which the
originator can market the drug without competition from generic
drug manufacturers) by the number of months that the review
period is shortened. The effectiveness of this approach and the
rules under which a PRV is awarded have been examined critically
(Sonderholm, 2009; Robertson et al., 2012; Sachs-Barrable et al.,
2014; Kesselheim et al., 2015). The ’case’ of miltefosine for treat-
ment of visceral leishmaniasis has pointed attention to the fact that
a PRV can be awarded to an organisation which has not itself
invested signiﬁcant funds in the development and for a drug which
has already been registered in another country for the neglected
disease indication. One important factor in the effectiveness of the
PRV is its market value. This has increased over time with the last
PRV sold for US $350 Million (see Table 2 for the website reference
which also includes other information on the PRV).
2. Research for new drugs for onchocerciasis control and
elimination
Table 4 provides an overview of ongoing research by type of drug
and stage of research classiﬁed as per Fig. 4. Based on the deﬁnitions
in the ICH guidelines, all of the drugs and drug regimens in Table 4
are ’investigational products’ (see Table 3 for deﬁnition). The prob-
ability that adverse reactions (see Table 3 for deﬁnition) are identi-
ﬁed which prohibit further development, registration or use, is
lower when drugs are investigated which have already been
approved at other doses, in other formulations, in combinations and/
or for other indications for human use than for drugs without any
registration for human use. Similarly and because toxicity testing
required to register drugs for veterinary use is nearly as extensive as
the toxicity testing to register drugs for human use, compounds
which have already been approved for veterinary use are less likely
not to progress to clinical development than compounds not regis-
tered for veterinary use. Therefore, the overview of the drugs in
development is presented by regulatory approval history.
2.1. Drugs approved for human use for other indications
2.1.1. Clinical development of new combinations and treatment
regimens of drugs currently used for control and elimination of
onchocerciasis and lymphatic ﬁlariasis
The DOLF project (Death to Onchocerciasis and LymphaticFilariasis, for website see Table 2) is funded by the Bill and Melinda
Gates Foundation (BMGF). The DOLF objectives are (1) to optimize
MDA for LF with currently approved drugs and (2) to evaluate the
efﬁcacy of new combinations of the three drugs currently used for
the control of onchocerciasis and LF (ivermectin, albendazole, as
well as, outside Africa, diethylcarbamazine (DEC)) for onchocerci-
asis and LF. DEC is not used in onchocerciasis endemic areas of
Africa because it can cause severe Mazzotti reactions in people
highly infectedwithO. volvulus (Bird et al., 1980; Francis et al., 1985;
Fulford et al., 1987; Awadzi and Gilles, 1992).
Table 4 shows the studies ongoing to evaluate the efﬁcacy of
combination treatment regimens against O. volvulus. The rationale
for the addition of albendazole to ivermectin is based on the results
of prior clinical studies. These suggested an effect of albendazole on
adult worm fertility (Cline et al., 1992; Awadzi et al., 1995, 2003)
whichmight be larger with higher and repeated albendazole doses.2.1.2. Clinical development of antibiotics against the O. volvulus
symbiont Wolbachia
The discovery of intracellular bacteria in ﬁlarial nematodes
dates back to the 1970’s (Kozek and Marroquin, 1977) and research
into the role of Wolbachia on ﬁlarial development and the effect of
treatment with antibiotics to the 1990’s (Bosshardt et al., 1993;
Genchi et al., 1998). In 1999, the Special Programme for Research
and Training in Tropical Diseases (WHO/TDR) organized a meeting
on ’Wolbachia as targets for ﬁlarial control’ (Taylor et al., 2000) to
review the evidence from non-clinical studies, assess the potential
utility of drugs targetingWolbachia for the control of onchocerciasis
and LF and recommend research priorities.
Since then, it has been shown that Wolbachia is important for
viability and fertility of O. volvulus (Tamarozzi et al., 2011). The
results of a clinical study showing that depletion of Wolbachia re-
sults in O. volvulus sterility in people treated for 6 weeks with
100mg doxycycline (Hoerauf et al., 2000, 2001) have contributed to
the funding of a large anti-Wolbachia (A-WOL) research programme
by the BMGF (Table 2). The objectives of the A-WOL consortium are
to (1) evaluatemarketed antibiotics in O. volvulus infected people to
identify regimens which are efﬁcacious and safe with a dosing
regimen suitable for large scale use, and (2) to discover new anti-
Wolbachia compounds and develop them as appropriate to regis-
tration. The rationale and progress of this project have been
reviewed regularly (Taylor et al., 2014).
Numerous clinical studies in onchocerciasis (or LF) have been
conducted to examine the effect of different dose regimens of
doxycycline, rifampicin and azithromycin (Hoerauf et al., 2001,
2003; Debrah et al., 2006; Richards, Jr. et al., 2007; Specht et al.,
2008; Hoerauf et al., 2008a, 2009; Turner et al., 2010; Debrah
et al., 2015; Abegunde et al., 2016). To date, doxycycline has
shown the highest efﬁcacy. A modelling-based analysis of the data
from three clinical trials of different regimens of doxycycline
(Hoerauf et al., 2003, 2008b, 2009) concluded that there is no
Table 4
Overview of ongoing research for new drugs for onchocerciasis control and elimination.
Type of investigational drug Development phase
 Investigational regimens tested (country, estimated completion date, clinical
trial registry number)
Approved with different dosing regimens for other indications in humans
 New combinations and treatment regimens of ivermectin and albendazole (i.e. drugs
currently used for control and elimination of onchocerciasis and LF in Africa)
Community studies*
 Annual vs. biannual MDA with 400 mg albendazole þ ivermectin (Ivory
Coast, Dec 2017, NCT02032043)
 Annual vs. biannual MDA with albendazole 400 mg þ ivermectin (Liberia,
April 2017, NCT01905436)
Phase 2/3 clinical development*
 Annual vs. biannual treatment with ivermectin 200 mg/kg or 200 mg/kg
ivermectin þ800 mg albendazole (Ghana, April 2016, ISRCTN50035143)
 Biannual treatment with ivermectin 200 mg/kg with 0 mg, 400 mg or 800 mg
albendazole. (Ghana, June 2017, NCT02078024)
* all studies also assess efﬁcacy against soil transmitted helminths
 Antibiotics with activity against Wolbachia in in-vivo animal models Phase 2 clinical development
 Rifapentine 900 mg/d plus moxiﬂoxacin 400 mg/d for 14 or for 7 days,
doxycycline 200 mg/d for 4 weeks(Ghana, May 2017, ISRCTN43697583)
 New oral formulation of ﬂubendazole with higher systemic bioavailability Preclinical development
Time of decision on progression to clinical development unknown
Approved for use in animals
 Moxidectin Preparation of submission for regulatory review
Preparation of community studies and study to determine safe dose in
paediatric population
 Emodepside Phase 1 clinical development
 First in Human single ascending dose safety, tolerability and
pharmacokinetic study (United Kingdom, April 2016, NCT02661178)
New chemical entities
 Anti-wolbachia compounds Discovery/pre-clinical development
 Other compounds Discovery
MDA: mass drug administration, investigational regimens: regimens not used in CDTI or with regulatory approval for use in onchocerciasis.
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adult female O. volvulus containing Wolbachia between the regi-
mens (91%e94%) and that Wolbachia depletion results in a 70%e
80% reduction in the life span of O. volvulus macroﬁlariae (Walker
et al., 2015).
The long duration of doxycycline treatment (4 weeks) as well
as the safety proﬁle of doxycyline (Table 2) limit large scale use and
motivate ongoing research into the efﬁcacy of other antibiotics
(Table 4).
The clinical studies also showed that antibiotics have no acute
microﬁlaricidal effect and that the decrease in skin microﬁlariae
levels is due to microﬁlariae dying as they reach the end of their
natural lifespan. This suggests that antibiotics will have a safety
proﬁle suitable for use in Loa loa co-infected people. A study which
included Loa loa co-infected participants was conducted. No severe
adverse reactions of the type reported after ivermectin treatment of
people with high level of infection with Loa loa were reported.
However, Loa loa microﬁlaridermia in participants was <8000 mf/
ml (Turner et al., 2010). Since Loa loa does not contain Wolbachia
(Grobusch et al., 2003; Buttner et al., 2003), antibiotics are no po-
tential treatment for Loa loa infection.
Development of resistance to antibiotics is now recognized as a
global threat (http://www.who.int/drugresistance/DC_
Antimicrobial_Resistance/en/, accessed 16 January 2016). There-
fore, use of antibiotics for O. volvulus or other ﬁlarial infections
should include assessing the potential emergence of resistance of
bacteria and other human pathogens treated with tetracyclines to
ensure that use for parasitic infections does not negatively impact
the ability to effectively treat other infections.
2.1.3. Flubendazole
Flubendazole is a benzimidazole approved for treatment of
gastrointestinal nematodes in humans.
A clinical study conducted around 30 years ago in Mexico with
an injectable formulation showed that ﬂubendazole was veryefﬁcacious against O. volvulus macroﬁlariae (Dominguez-Vazquez
et al., 1983). At the time, the study was not completed due to in-
jection site inﬂammation.
The promise of ﬂubendazole as a macroﬁlaricide and the op-
portunities novel drug formulation techniques offer for an oral
formulation with high bioavailability was pointed out by Mack-
enzie and Geary (Mackenzie and Geary, 2011). In 2011, a partner-
ship betweenMichigan State University in the US, McGill University
in Canada and the Not-for-proﬁt organisation ’Drugs for Neglected
Diseases Initiative’ (DNDi) was formed to develop a suitable oral
formulation of ﬂubendazole and conduct the relevant pharmaco-
dynamic, pharmacokinetic and toxicology studies. The work of the
partnership was supported by a grant from the BMGF (Table 2). In
2012, Johnson&Johnson joined the initiative (Table 2). DNDi has
since completed its involvement in the project with transfer of all
data to Johnson&Johnson (for website reference see Table 2).
New oral formulations have been developed (Ceballos et al.,
2009, 2014). An oral formulation with higher systemic bioavail-
ability than the formulations used for treatment of intestinal
nematodes requires additional preclinical toxicology and pharma-
cotoxicity studies in view of the fact that ﬂubendazole interferes
with microtubules and can thus have reproductive toxicity
(Mackenzie and Geary, 2011). Results of the ﬁrst pre-clinical toxi-
cology studies conducted have been published (Longo et al., 2013,
2014; Tweats et al., 2015).
The assessment of the results of the pre-clinical toxicology
studies will determine whether an oral formulation can be devel-
oped clinically for MDA, for ’selective MDA’ (deﬁned here as MDA
excluding subpopulations susceptible to speciﬁc toxicity e.g.
women of reproductive age due to reproductive toxicity), or for
’diagnosis-supportedMDA’ (deﬁned here asMDAwhich speciﬁcally
identiﬁes subpopulations with contraindications (e.g. pregnant
women)). A ’diagnosis-supported MDA’ approach, referred to as
’Test&Treat’ approach, is currently being evaluated for ivermectin
treatment for onchocerciasis in loiasis co-endemic areas
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The data available from animal models and humans do not
suggest that ﬂubendazole kills microﬁlariae. Therefore, ﬂubenda-
zole is a very promising candidate for MDA in Loa loa co-endemic
areas. Even if its safety proﬁle should require ‘selective MDA’ or
’diagnosis-supported MDA’, ﬂubendazole would be a very valuable
tool for control and elimination of onchocerciasis: treatment of
even only the male adult populationwould signiﬁcantly reduce the
burden of infection and transmission and reduce the population
whose infections would need to be addressed with more individ-
ualized approaches.
Flubendazole should also be evaluated for its efﬁcacy against Loa
loa itself. Loiasis is not only an impediment to onchocerciasis and LF
elimination, but also a neglected disease that puts a health burden
on those infected (Andy et al., 1981; Nutman et al., 1986; Lukiana
et al., 2006; Boussinesq, 2006). No effective and safe treatment is
available. Given that albendazole has some limited effect on Loa loa
(Kamgno et al., 2016) and current data on the relative effect of
albendazole and ﬂubendazole on O. volvulus, ﬂubendazole may
have anti-Loa loa efﬁcacy.
Information on whether and when an oral formulation of ﬂu-
bendazole has or is expected to enter clinical development is not
publicly available.
2.2. Drugs with proven efﬁcacy in animal helminth infections but
not approved for human use
Drugs developed for veterinary use are the ’classical’ source of
compounds for development for human helminth infections. Two
drugs approved for veterinary use are currently in development for
onchocerciasis.
2.2.1. Moxidectin
Moxidectin is, as ivermectin, albendazole and mebendazole,
registered for treatment of different types of nematodes in animals.
Both ivermectin andmoxidectin contain a macrocyclic lactone ring,
but ivermectin is an avermectin, while moxidectin is a milbemycin
(Prichard et al., 2012). Research into moxidectin’s potential to have
a higher effect on O. volvulus viability and/or fertility than iver-
mectin was initiated by WHO/TDR in the late 1990’s (Tagboto and
Townson, 1996). Five Phase 1 studies in healthy volunteers were
conducted (Cotreau et al., 2003; Korth-Bradley et al. 2011, 2012,
2013, 2014). A Phase 2 study in Ghana determined whether mox-
idectin was safe enough in O. volvulus infected people to be eval-
uated in a Phase 3 study and obtained initial efﬁcacy data (Awadzi
et al., 2014). A Phase 3 study in 12 year olds with 10 micro-
ﬁlariae/mg skin was conducted in areas in Ghana, Liberia and the
Democratic Republic of the Congo where CDTI had not yet been
implemented at the time of participant recruitment (Opoku et al.,
2013; Kanza et al., 2013; Bakajika et al., 2013). In both, the Phase
2 and the Phase 3 study, moxidectin was more efﬁcacious in
reducing skin microﬁlariae levels than ivermectin. More impor-
tantly, moxidectin prevented repopulation of the skin with micro-
ﬁlariae more effectively than ivermectin: skin microﬁlariae levels
12 months after moxidectin treatment were similar to those one
month after ivermectin treatment (Opoku et al., 2013). Modelling of
the effect of annual mass administration of moxidectin suggested
that annual MDA of moxidectin can reduce time to onchocerciasis
elimination relative to annual CDTI to an extent comparable to that
achieved by biannual CDTI (Turner et al., 2015). The Australian Not-
for-Proﬁt organisation ’Medicines Development for Global Health’
(MDGH) to whom WHO has licensed all data available to WHO,
intends to register moxidectin for onchocerciasis. MDGH will also
sponsor a study to determine a paediatric dose and a large com-
munity study. MDGH furthermore intends to develop moxidectinfor LF and scabies.
MDGH received the funds for the work required to prepare
registration of moxidectin for onchocerciasis with the US FDA from
the Global Health Investment Fund (GHIF). The fact that the US FDA
would award a PRV if moxidectinwas registered played a role in the
GHIF funding decision (Table 2).
2.2.2. Emodepside
Emodepside is a cyclooctadepsipeptide registered in Europe and
the US as a combination product with praziquantel for treatment of
cats infected with or at risk of infection with intestinal nematodes
(Toxocara cati Toxascaris leonina, Ancylostoma tubaeforme) and
cestodes (adult Dipulidium caninum, Taenia taeniaeformis, Echino-
coccus multilocularis) and as a combination product with toltrazuril
for treatment of dogs with demonstrated or suspected infection
with nematodes (Toxocara canis, Uncinaria stenocephala, Ancylos-
toma caninum, Trichuris vulpis) and coccidia (Isospora ohioensis,
Isospora canis). Emodepside acts at the neuromuscular junction and
has a unique mechanism of action relative to other antiﬁlarial
drugs, which is not yet fully understood (Harder and von Samson-
Himmelstjerna, 2002; Harder et al., 2003, 2005; Willson et al.,
2003; von Samson-Himmelstjerna et al., 2005; Krucken et al., 2012;
Epe and Kaminsky, 2013; Kulke et al., 2014; Crisford et al., 2015).
Pre-clinical pharmacology studies in in-vitro and in-vivo models of
human ﬁlarial infections, including onchocerciasis models, spon-
sored in the early 2000s by WHO/TDR showed promising data
(WHO/TDR, 2005; Townson et al., 2005). These contributed to
emodepside being proposed as a candidate for development for
human use (Olliaro et al., 2011).
In 2014, DNDi and Bayer HealthCare completed a legal agree-
ment for collaboration on development of emodepside (Table 2).
Clinical development has been initiated with the ﬁrst study in
humans to determine the safety, tolerability and pharmacokinetics
of emodepside in healthy male volunteers (Table 4).
2.3. Discovery of new compounds
2.3.1. New anti-wolbachia drugs or drug combinations
The A-WOL consortium has developed a Wolbachia cell-based
assay for screening different compound libraries for compounds
with activity against Wolbachia. The approach and results from
screening of compounds already approved or in development for
human use has recently been reviewed (Johnston et al., 2014).
Relative to the success rates shown in Fig. 4, it is noteworthy that
historically antibiotics progressing from discovery and pre-clinical
research into clinical development have a higher success rate
than many other types of drugs with around 17% registered for
human use (Kola and Landis, 2004). Assuming that no commercial
considerations will interfere in progressing compounds identiﬁed
by the A-WOL consortium into pre-clinical and clinical develop-
ment, the success rate for anti-Wolbachia drugs could be even
higher.
2.3.2. Other compounds with activity against O. volvulus
A partnership of different research centres is funded by the
BMGF for discovery of compounds which are cidal to O. volvulus in
pre-clinical models and can be transitioned to preclinical toxi-
cology studies (Table 2).
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